

RESEARCH

Open Access



Clinical and immunological outcomes of HIV-exposed uninfected and HIV-unexposed uninfected children in the first 24 months of life in Western Kenya

Jessica E. Ray^{1†}, Katherine R. Dobbs^{1,2*†}, Sidney O. Ogolla³, Ibrahim I. Daud³, David Midem³, Maxwel M. Omenda³, Amy S. Nowacki⁴, James G. Beeson⁵, Katherine R. Sabourin⁶, Rosemary Rochford⁶ and Arlene E. Dent^{1,2*}

Abstract

Background Previous studies show increased morbidity in children who are HIV-exposed but uninfected (HEU) compared to children who are HIV-unexposed uninfected (HUU). We sought to evaluate the effects of prenatal HIV exposure on clinical and immunological outcomes in the first 24 months of life.

Methods Eighty-five HEU and 168 HUU children from Kenya were followed from birth to 24 months. All mothers living with HIV received combination antiretroviral therapy. Children who were HEU received standard-of-care cotrimoxazole prophylaxis through 18 months. Episodes of acute illness were identified through a combination of active and passive follow up. Trajectories of plasma cytokines, vaccine-specific antibodies, and antimalarial antibodies were examined.

Results Children who were HEU and children who were HUU had similar growth curves. Children who were HEU had lower rates of malaria (rate ratio 0.54, 95% CI 0.38, 0.77) and respiratory illness (rate ratio 0.80, 95% CI 0.68, 0.93). Trajectories of plasma cytokines and vaccine-specific antibodies were similar in children who were HEU and HUU. There were subtle differences in antimalarial antibody dynamics, in which children who were HEU had overall lower antibody levels against five of the 14 malaria antigens tested.

Conclusions Children who were HEU and born to optimally treated mothers living with HIV had similar growth characteristics and immune profiles compared to children who were HUU. Children who were HEU had reduced risk for malaria and respiratory illness, which may be secondary to cotrimoxazole prophylaxis.

Keywords HIV-exposed uninfected, HEU, HIV, Malaria, Infant, Child, Growth, Cytokine, Vaccine, Antimalarial antibodies

[†]Jessica E. Ray and Katherine R. Dobbs contributed equally to this work.

*Correspondence:

Katherine R. Dobbs

kxd179@case.edu

Arlene E. Dent

aed9@case.edu

Full list of author information is available at the end of the article



Background

HIV continues to be a major public health threat, especially in sub-Saharan Africa. Maternal HIV infection is a risk factor for adverse pregnancy and birth outcomes for millions of maternal-neonatal dyads, including maternal and fetal anemia, preterm birth, and low birth weight [1]. Antiretroviral therapy (ART) during pregnancy prevents mother-to-child transmission of HIV and improves maternal health [2–5]. Currently, most HIV-infected pregnant women have access to ART [6]. In sub-Saharan Africa, 69% of HIV-infected pregnant women had access to ART in 2019 [7]. With increased access to ART there is a growing population of HIV-exposed but uninfected (HEU) infants. The estimated number of HEU infants reached 14.8 million in 2018, and of these 13.2 million are from sub-Saharan Africa [8].

Infants who are HEU are healthier than HIV-infected infants [9], but several studies have shown that infants who are HEU have greater morbidity and mortality than HIV-unexposed uninfected infants (HUU) [10]. HEU infants have been shown to have a greater frequency of all-cause sick clinic visits [11], greater infection rates [12], and a 1.2–2.7 times greater risk of hospitalization [13, 14] compared with HUU infants. Mortality rates for HEU infants have been shown to be 3–4 times greater than in HUU infants [9, 15]. The underlying mechanisms for these observations are likely multifactorial and may be influenced by parental illness and death, increased infectious exposures, impaired placental transfer of protective maternal antibodies, antiretroviral therapy exposure in utero, and subsequent immune modulations.

Many of these conclusions were drawn from studies performed prior to the widespread implementation of optimal HIV therapies during pregnancy. We have previously examined the immunological consequences of maternal HIV infection among a maternal–neonate cohort of HIV-infected women on ART and women without HIV infection living in a malaria-endemic area of western Kenya [16]. Our results showed that even in optimally treated HIV-infected women, defects in transplacental transfer of antimalarial antibodies persisted, though we found no effect of maternal HIV infection on birth outcomes, cord blood plasma cytokine profiles, or transplacental transfer of vaccine-specific antibodies. Here, we report on 24 months of follow up for children who are HEU and HUU in this cohort with investigations of growth trajectories, rates of malaria and other common childhood illnesses, and trajectories of plasma cytokine profiles, vaccine-specific antibodies, and antimalarial antibodies.

Methods

Ethical approval

Informed consent was obtained in the appropriate local language. Ethical approval was obtained from the University Hospitals Cleveland Medical Center IRB (08–07-09), Colorado Multiple IRB (15–1277), and Kenya Medical Research Institute (KEMRI) Scientific and Ethical Review Unit (NON SSC 089).

Study site and participants

The study was conducted in Kisumu County, Kenya, at the Chulaimbo Sub-County Hospital, from 2011–2016. Malaria transmission in this area is intense and year-round, with peaks coinciding with rainy seasons [17]. Chulaimbo Hospital serves a primarily rural population and is an Academic Model Providing Access to Healthcare (AMPATH) site. Clinical services and medications for HIV-infected patients and their families are supported by USAID and the Indiana University–Kenya partnership.

Participants were enrolled in a prospective observational study in which pregnant women with and without HIV infection were enrolled at their first prenatal visit (typically during the second trimester) and followed through pregnancy. Inclusion criteria for participation included (i) residency within a 10 km distance of the hospital, (ii) uncomplicated vaginal delivery, and (iii) singleton pregnancy. Exclusion criteria included (i) twin deliveries, (ii) blood transfusion ≤ 24 h before delivery, (iii) other non-HIV infections besides malaria, and (iv) complications during pregnancy. Infants were followed from birth to 24 months of age. All women living with HIV received ART therapy. ART regimens included a backbone of Lamivudine + Zidovudine if Hb > 8 g/dL or Lamivudine + Tenofovir if Hb < 8 g/dL, along with Nevirapine if CD4 count < 250 cells/ μ L or Lopinavir/ritonavir if CD4 count > 250 cells/ μ L. HEU newborns were treated with one dose of Nevirapine after delivery and 6 weeks of Zidovudine, with zero HIV-infected infants in this cohort.

Eighty-five HEU and 168 HUU children with complete clinical data and samples were included in this study. Study visits occurred at birth and at 6, 10, 14, and 18 weeks and 6, 9, 12, 15, 18, 21, and 24 months of age. The Kenya Expanded Programme on Immunization schedule included diphtheria-pertussis-tetanus (DPT), *Haemophilus influenzae* type b (Hib), hepatitis B, oral polio (OPV) and pneumococcus (PCV) vaccines at 6, 10, and 14 weeks and measles vaccine at 9 and 18 months of age. According to Kenyan Ministry of Health guidelines, HEU infants received cotrimoxazole prophylaxis from 6 weeks of age until cessation of breastfeeding

and definitive exclusion of HIV infection (typically at 18 months of age).

Clinical events

Data collected during each visit included clinical history, physical exam and anthropometric measurements, and any concurrent diagnoses (e.g., upper respiratory tract infection, malaria, gastroenteritis). Participants were seen at the study clinic for any interim sick visits, where data were collected regarding physical exam findings, diagnoses, treatments given, and severity of illness (any illness that required hospitalization was classified as severe). Major diagnostic categories from interim or concurrent sick visits included clinical malaria (defined as febrile illness with *Plasmodium falciparum* (Pf) parasitemia by blood smear or rapid diagnostic test), upper respiratory tract infection (URTI), any respiratory illness, gastroenteritis/diarrhea, and any severe illness.

Blood sample collection and processing

At delivery, venous cord blood samples were collected in heparinized syringes. At all other visits, heparinized finger prick or venous blood samples were obtained. Aliquots of 200 μ L whole blood were stored at -20 °C. Plasma was separated and stored at -80 °C. All sample processing occurred within 1–5 h of collection at the laboratory facilities at the Center for Global Health Research of KEMRI. All assays were conducted at the KEMRI laboratories.

Detection of Pf infection by PCR

To determine the prevalence of asymptomatic Pf infection in the cohort, Pf PCR was performed on all available samples at 6, 9, 12, 15, 18, 21, and 24 month visits. DNA was extracted from whole blood using Qiagen QIAmp DNA Mini Kits. Pf PCR was performed as previously described [18].

Measurement of cytokines

Immunological assays were performed for a subset of children with plasma samples available at all timepoints. We measured levels of 12 cytokines in plasma samples from 59 HEU and 58 HUU children at birth, 6, 10, 14, 18, 26, 39, and 52 weeks of age. All plasma samples were assayed immediately after initial thawing. A multiplexed bead-based immunoassay was used to measure plasma concentrations of IFN- γ , IL-1 β , IL-6, IL-10, IL-12P70, IL-17A, IL-17E, IL-17F, IL-21, IL-22, IL-23, and TNF (Human Th17 Magnetic Bead Panel, EMD Millipore).

Vaccine-specific IgG

We measured IgG antibodies to diphtheria, tetanus, hepatitis B, and measles in plasma from 61 HEU and

54 HUU children by ELISA, as previously described [16, 19, 20]. Time points included birth, 6, 10, 14, and 18 weeks, and 6, 9, 12, 15, 18, 21, and 24 months. Serial dilutions of samples were compared with 5-point standard curves made with serial dilutions from World Health Organization–approved antigen-specific reference sera; diphtheria Ig, human (NIBSC 10/262, 2 IU/mL), tetanus Ig, human (NIBSC TE-3, 120 IU/mL), hepatitis B Ig, human (NIBSC 07/164, 100 IU/mL), and measles Ig, human (NIBSC 97/648, 3 IU/mL).

Pf antigen-specific IgG

We measured IgG antibodies to 14 recombinant Pf proteins in plasma samples from 69 HEU and 76 HUU children using Luminex MagPix assays (MagPlex, Luminex). Time points included birth, 6, 10, 14, and 18 weeks, and 6, 9, 12, 15, 18, 21, and 24 months. The assays were performed as previously described [16, 21]. Supplementary Table 1 contains sources and quantities of conjugated antigens. For each assay, plasma was diluted 1:100 and 1:1000. The secondary antibody was R-Phycoerythrin-conjugated AffiniPure F(ab') Fragment Goat Anti-Human IgG Fc γ Fragment Specific (Jackson ImmunoResearch, West Grove, PA). Seven malaria-naïve North American adult plasma samples were tested on all plates as negative controls. Mean fluorescent intensity (MFI) values were divided by average MFIs of negative controls. Data are expressed as the fold-increase of the sample MFI relative to the negative control MFI (reported as fold over North American), as previously described [21].

Statistical analysis

World Health Organization (WHO) child growth standards were used to generate Z scores for weight-for-age (WAZ), length-for-age (LAZ), head circumference for age (HAZ), and body mass index (BMI) for age (BAZ) (WHO Anthro Survey Analyser, R package “anthro” v0.9.4) [22]. Bayesian hierarchical regression analysis was used to fit WAZ, LAZ, HAZ, and BAZ linear growth curve models for the HEU vs. HUU groups, which accounts for both individual-specific effects and group-level effects. All models were fit using JAGS software via the R package “rjags” [23, 24]. Missingness in the data was assumed to be completely at random. Prior distributions for group means for intercept and slope were weakly informative and specified as normal distributions with mean 0 and variance 100. Standard non-informative uniform distributions were specified for the residual variance and the standard deviations of intercept and slope. Posterior distributions were checked for convergence graphically and numerically using the \hat{R} statistic; convergence criteria with $\hat{R} < 1.1$ were met for all parameters for all models. For each

growth curve model, posterior means for intercepts and slopes, with 95% highest probability density interval (HDI), were contrasted between HEU vs. HUU groups. We selected a region of practical equivalence (ROPE) with upper and lower limits of -0.05 and 0.05; contrast terms for group intercepts and slopes were deemed to be meaningfully different if the 95% HDI excluded this interval.

The prevalence of asymptomatic Pf infection among HEU and HUU infants was calculated at 6, 9, 12, 15, 18, 21, and 24 months of age. The relative risk of Pf infection in the HEU group compared to the HUU group was determined at each time point.

Clinical event rates for the major diagnostic categories (malaria, URTI, any respiratory illness, gastroenteritis/diarrhea, and severe illness) were calculated by the number of diagnoses per 1,000 person-months of follow up in each group. Rate ratios were calculated as the ratio of clinical event rates in HEU children divided by the clinical event rates in HUU children.

Time fixed effects regression models were used to analyze plasma cytokines, vaccine antibodies, and antimalarial antibodies in HEU vs. HUU children. We first tested whether trajectories differed among HEU vs. HUU children ("group x time" interaction effects). Then if the trajectories did not differ, we tested whether values for HEU children differed from values for HUU children ("group" main effect) and whether the values changed over time within a group ("time" main effect).

Results

Similar growth curves in children who were HEU and HUU

Birth characteristics for the cohort of 85 children who were HEU and 168 children who were HUU are listed in Supplementary Table 2. There were no differences in gestational age at delivery, birth weight, length, or head circumference between children who were HEU vs. HUU. Mean gestational age was 37.2 ± 4.4 weeks in children who were HEU and 38.2 ± 3.8 weeks in children who were HUU. Mean birth weight was 3.2 ± 0.5 kg in both groups. The proportion of low birth weight was 8.4% in children who were HEU and 6.1% in children who were HUU (Chi-squared test $p=0.7$). Growth curve trajectories for weight, length, and head circumference were similar among HEU and HUU children from birth to 24 months of age (Fig. 1). Linear growth curve models for Z scores for weight, length, head circumference, and BMI for age obtained using Bayesian hierarchical regression showed no statistically meaningful differences in HEU vs. HUU children (contrast terms for intercepts and slopes comparing each of the four

growth curves for HEU vs. HUU were not credibly different from zero) (Supplementary Table 3).

Lower rates of *P. falciparum* infection and respiratory illness in children who were HEU vs. HUU

The prevalence of asymptomatic Pf infection was measured at seven timepoints between 6 and 24 months of age in HEU and HUU groups. Children who were HEU had reduced relative risk of Pf infection compared to children who were HUU at 18 months of age (RR=0.49, 95% CI 0.31, 0.78) (Fig. 2A). There were no statistically significant differences in relative risk for Pf infection at the other timepoints.

Clinical event rates, including at scheduled follow-up visits and interim sick visits, were compared between HEU and HUU children between birth and 24 months of age (Fig. 2B). Children who were HEU had lower rate ratios for malaria (0.54, 95% CI 0.38, 0.77), URTI (0.77, 95% CI 0.62, 0.94), and any respiratory illness (0.80, 95% CI 0.68, 0.93). There was no difference in gastroenteritis/diarrhea between the groups. The rate ratio for severe illness requiring hospitalization was lower in children who were HEU vs. HUU, though this difference did not reach statistical significance (rate ratio = 0.59, 95% CI 0.34, 1.02).

Similar plasma cytokine trajectories in children who were HEU and HUU

Trajectories for plasma levels of 12 cytokines were compared for 59 HEU vs. 58 HUU children at eight timepoints between birth and 52 weeks of age using fixed effects regression models (Fig. 3). There were no significant interaction effects between group and time for any of the 12 cytokines measured, indicating that the trajectories of these plasma cytokines did not differ between children who were HEU vs. HUU (Supplementary Table 4). We then evaluated the main effects for group for each of the cytokines. There was evidence for lower IL-22 levels in children who were HEU (mean 4.9 ng/mL) compared to children who were HUU (mean 5.7 ng/mL) (main effects $p=0.01$). There was no evidence that plasma levels of the other 11 cytokines differed between children who were HEU vs. HUU. Finally, we evaluated the main effects for time to determine whether plasma cytokine levels changed over time independent of group and whether there were significant differences in cytokine levels at birth vs. 26 weeks (6 months) of age. For all 12 cytokines tested, the values did change over time. Specifically, 11 out of 12 cytokines were significantly higher at 26 weeks compared to birth, with the exception of IL-6 which showed no significant difference (Supplementary Table 4).




Fig. 1 Similar growth curves in HEU and HUU children. Growth curves for (A) weight, (B) length, and (C) head circumference for age were assessed at 12 visits between birth and 24 months of age in male and female HUU (blue) and HEU (red) children. Mean and standard deviation at each time point plotted on the y-axis




Fig. 2 Rates of *P. falciparum* infection and clinical event rates in HEU and HUU children. **A** Relative risk of *P. falciparum* infection in HEU vs. HUU children between 6 and 24 months of age. *P. falciparum* infection detected by PCR. Relative risk less than one represents decreased risk in HEU children (point estimates and 95% confidence intervals displayed). **B** Differences in rates of clinical events in HEU vs. HUU children between birth and 24 months of age. Rate ratio less than one represents decreased rate in HEU children (point estimates and 95% confidence intervals displayed). URTI: upper respiratory tract infection

Similar vaccine antibody trajectories in children who were HEU and HUU

Total IgG antibody responses to vaccines for diphtheria, tetanus, hepatitis B, and measles were compared between 61 HEU and 54 HUU children. Antibody concentrations were measured at 12 timepoints between birth and 24 months of age (Fig. 4). Fixed effects regression models were used to compare vaccine antibody trajectories between children who were HEU vs. HUU

(Supplementary Table 5). There were no significant interaction effects between group and time for diphtheria, hepatitis B, and tetanus specific antibodies, indicating that the trajectories of these antibodies did not differ between children who were HEU vs. HUU. There was a significant interaction effect between group and time for measles-specific antibodies ($p=0.03$). Separation between HEU and HUU trajectories appeared to occur beginning at 18 months of age (around the time that the




Fig. 3 Twelve plasma cytokine trajectories in HEU and HUU children. Cytokines include IFN- γ , IL-1 β , IL-6, IL-10, IL-12p70, IL-17A, IL-17E, IL-17F, IL-21, IL-22, IL-23, and TNF. HUU (blue) compared to HEU (red). Mean cytokine values plotted on the y-axis with error bars representing one standard error from the mean. Age (weeks) between birth and one year represented on the x-axis

second dose of measles vaccine is given), with higher anti-measles antibodies in children who were HUU (Fig. 4A). These data suggest that children who were HUU may have a heightened antibody response to the second measles vaccine dose compared to children who were HEU, though both groups of children generated antibody responses to the vaccine at levels associated with protection [25].

Because the separation between groups for anti-measles antibodies appeared to occur at the very end of the observation period, we proceeded with an additive model for all four vaccines. We evaluated the main effects for group which showed insufficient evidence that children who were HEU vs. HUU differed with respect to overall levels of any of the vaccine antibodies tested (Supplementary Table 5). Finally, we evaluated the main effects for time to determine whether vaccine specific antibody levels changed over time independent of group and whether there were significant differences in antibody levels at birth, 6 months, and 18 months of age. All four vaccine-specific antibody levels changed significantly over time, with rises in antibody levels coinciding with time of vaccination (18 weeks for diphtheria, tetanus and hepatitis B, and 9 months for measles) (Fig. 4, Supplementary Table 5).

Differences in antimalarial antibody trajectories in children who were HEU vs. HUU may reflect differences in incidence of *P. falciparum* infection

Antimalarial IgG antibodies to 14 Pf antigens were compared between 76 HEU and 69 HUU children. Antibody concentrations were measured at 12 timepoints between birth and 24 months of age (Fig. 5). Fixed effects regression models were used to compare antimalarial antibody trajectories between children who were HEU vs. HUU (Supplementary Table 6). There were no significant interaction effects between group and time for ten of the 14 antigens (CSP, EBA-140, EBA-175, EBA-181, MSP1, MSP3, MSP7, MSP9, MSP DBL2, and Rh5). Significant interaction effects between group and time were observed for four of the 14 antigens: AMA1-3D7 ($p=0.001$), MSP2 ($p=0.01$), MSP6 ($p=0.0002$), and MSP DBL1 ($p=0.02$) (Supplementary Table 6). There were no consistent patterns for differences in children who were HEU vs. HUU in trajectories of antibodies to these four antigens. Anti-MSP DBL1 antibody levels were slightly lower for HEU vs. HUU children at 18 and 24 months; anti-AMA1-3D7 antibodies were slightly lower for children who were HEU across all timepoints (Fig. 5). Given the slight differences between children who were HEU vs. HUU in trajectories for anti-AMA1-3D7 and MSP




Fig. 4 Trajectories of vaccine specific antibody levels in HEU and HUU children. Vaccine-specific antibody levels were measured for (A) Diphtheria, (B) Tetanus, (C) Hepatitis B, and (D) Measles vaccines. HUU (blue) compared to HEU (red). Age (birth to 24 months) is on the x-axis and vaccine specific antibody levels (IU/mL) are on the y-axis (mean with error bars representing one standard error from the mean)

DBL1 antibodies, and the high degree of variability in the data, we proceeded with an additive model for these two antigens. The effect of HIV exposure on anti-MSP2 and anti-MSP6 antibody levels depended on age, with opposite correlations observed for each antigen. Children who were HEU had lower anti-MSP2 antibodies compared to children who were HUU prior to 6 months of age, but after 6 months of age, children who were HEU had higher levels. Conversely, children who were HEU had higher anti-MSP6 antibodies compared to children who were HUU prior to 6 months of age, but after 6 months of age, children who were HEU had lower levels. (Fig. 5). We concluded that trajectories for anti-MSP2 and anti-MSP6 antibodies significantly differed between children who were HEU vs. HUU. Therefore, for these two antigens, we did not proceed to test main effects for group (to determine whether overall values differed in HEU vs. HUU) or main effects for time (to determine whether antibody values changed over time independent of group).

We evaluated main effects for group for 12 of the 14 antigens and found that children who were HEU vs. HUU significantly differed with respect to five of the 12 antigens included in the analysis: CSP, AMA1-3D7, MSP3, MSP9, and MSP DBL1. For all five of these antigens,

children who were HEU had lower antibody levels than children who were HUU (Fig. 5, Supplementary Table 6).

We then evaluated main effects for time for the same 12 antigens, testing whether antibody levels changed over time in all subjects independent of group and whether there were significant differences in mean antibody levels at birth, 26 weeks (6 months), and 78 weeks (18 months) of age. For all twelve antibodies, values significantly changed over time ($p < 0.0001$) (Supplementary Table 7). Mean antibody levels were significantly lower at 6 months of age compared to birth for all twelve antigens included in this analysis ($p < 0.0001$). All mean antibody levels were higher at 18 months compared to 6 months, but the difference was statistically significant for only nine of the twelve antibodies tested (Supplementary Table 7).

Discussion

Results from this cohort study in western Kenya indicate that children who were HEU and born to mothers receiving ART had similar growth characteristics and immune profiles compared to children who were HUU. Notably, children who were HEU in this cohort had reduced risk for malaria and respiratory illness in the first 24 months of life, presumably secondary to standard of care for children who were HEU in this high malaria transmission




Fig. 5 Fourteen anti-malarial antibody trajectories in HEU and HUU children. Malarial antigens include CSP, AMA-1 3D7, EBA-140, EBA-175, EBA-181, MSP1, MSP2, MSP3, MSP6, MSP7, MSP9, MSP DBL1, MSP DBL2, and RH5. HUU (blue) compared to HEU (red). Mean antibody values (fold over North American controls) plotted on the y-axis with error bars representing one standard error from the mean. Age (weeks) between birth and two years is plotted on the x-axis

area that includes cotrimoxazole prophylaxis from 6 weeks of age until cessation of breastfeeding and exclusion of HIV infection (~ 18 months of age).

Several studies conducted in sub-Saharan Africa demonstrate impaired weight gain and growth in children who were HEU compared to HUU [26–29]. The widespread implementation of lifelong ART for all HIV-infected pregnant women (“Option B+”) may have a positive impact on infant and child growth. A study in Malawi compared growth in HEU children before and after Option B+ was implemented and found that post-natal weight gain was faster in HEU children born during the Option B+ period [30]. A large prospective study

of children who were HEU and HUU in South Africa in the context of Option B+ with breastfeeding showed that children who were HEU had small deficits in growth trajectories in the first 12 months of life, though overweight was common in both HEU and HUU infants at 12 months [31]. A study in Rwanda showed considerable heterogeneity in growth patterns of both HEU and HUU children, in which birth characteristics such as infant sex, birth weight, and maternal height were predictive of growth trajectories in both groups [32]. In this study, we did not detect a significant difference in growth trajectories between children who were HEU vs. HUU. Ongoing surveillance and research are needed to fully

assess the impact of maternal HIV and ART exposure on child growth and metabolism in the context of universal maternal ART.

Numerous studies over the past several decades have shown increased infection-related morbidity and mortality in children who were HEU vs. HUU [9, 10, 12–15, 33, 34]. In the current study, we observed an opposite trend in which children who were HEU had fewer episodes of malaria and respiratory illness compared to children who were HUU. As with child growth, universal maternal ART likely has a positive impact on infectious morbidity in children who were HEU. Infants born to mothers without virological control during pregnancy have high rates of undernutrition and serious infectious morbidity [35], and pre-conception ART is associated with reduced risk for infection-related hospitalization [36].

Our cohort study took place in an area with intense year-round transmission of malaria. We suspect that in the context of universal maternal ART and breastfeeding, anti-malarial activity of cotrimoxazole underlies the decreased rates of *P. falciparum* infection and clinical malaria in children who were HEU vs. HUU [37–40]. While the WHO continues to recommend cotrimoxazole prophylaxis for all infants who are HEU [41], recent randomized trials observed no benefit of cotrimoxazole prophylaxis for HEU infants living in non-malarial areas of Botswana [42] and South Africa [43]. Evidence from these trials, along with dramatic improvements in access to ART and healthcare for mothers and infants over the past 20 years, suggest that routine cotrimoxazole prophylaxis is not beneficial for all infants who are HEU [44]. However, potential benefits of cotrimoxazole prophylaxis observed in this study and in other malaria hyper-endemic settings [39, 40] suggests the need to further develop perennial malaria chemoprevention strategies targeting all children independent of HIV exposure.

We did not observe significant differences in plasma cytokine trajectories over the first year of life. We did observe overall lower levels of IL-22 in children who were HEU. HIV exposure in adults has been associated with altered Th22 responses, though further research is needed to evaluate possible mechanisms underlying altered systemic levels of IL-22 in children who are HEU [45]. In the same cohort, we observed lower levels of peripheral blood plasma cytokines in HIV-infected vs. HIV-noninfected mothers at delivery, though we did not see differences in cord blood plasma cytokine levels in HEU vs. HUU neonates [16]. As with clinical outcomes of child growth and infection-related morbidity, maternal access to ART in pregnancy likely plays a significant role in fetal and infant immune development. A recent study examined innate immune cytokine responses in maternal peripheral blood, placental blood, and neonatal

cord blood and found that the effects of HIV on maternal and infant innate immunity were restricted to women who did not receive ART before pregnancy [46]. Multifactorial influences on infant immune development were highlighted in another recent study that examined immune and microbiome differences in HEU vs. HUU 2-year-olds across diverse geographical settings [47]. The study revealed immune differences between children who were HEU and HUU that were site-specific: differences in innate immune responses distinguished children who were HEU vs. HUU in Belgium and Canada, though no immune differences were noted between South African children who were HEU vs. HUU [47]. These results suggest that, depending on the setting, other factors may influence immune phenotypes such that any effect of HIV or ART exposure is no longer evident.

In this study, longitudinal antibody responses to vaccination against diphtheria, hepatitis B, tetanus, and measles were similar in children who were HEU and HUU. Our results did suggest that children who are HUU may have a heightened response to the second dose of measles vaccine compared to children who are HEU, though both groups generated levels of anti-measles antibodies associated with clinical protection [25]. This is in line with prior studies showing that children who are HEU generally mount robust antibody responses to vaccines, including pneumococcal conjugate, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type B [48–51]. It is not clear why children who were HEU may have had decreased immunogenicity following the booster dose of measles vaccine at 18 months of age. One might speculate that cotrimoxazole prophylaxis could be associated with decreased vaccine responses. However, a large multi-site study of the potential impact of another sulfa drug, sulfadoxine-pyrimethamine, given as intermittent preventive treatment for malaria during infancy, showed that it had no effect on antibody responses to measles vaccination [52].

We did observe differences between children who were HEU vs. HUU in overall levels of antimalarial antibodies against five of 14 Pf antigens studied, in which antibody levels were lower in children who were HEU. We suspect this may reflect differences in rates of Pf infection and clinical malaria in children who were HEU, though more research is needed to confirm these findings and to determine whether these differences have any impact on long-term acquisition of clinical immunity to malaria.

Limitations of our study include a small sample size and potential that the results from this cohort may not be generalizable to all women and infants living in the region. While our overall cohort included 85 children who were HEU and 168 children who were HUU, a subset of samples were utilized for plasma cytokine and

antibody assays. It is possible that bias is introduced when analyzing only this subset of participants for which samples were available. In addition, the older ART regimens used at the time of this cohort study may not reflect what is seen with updated regimens. However, given the high rates of viral suppression with dolutegravir-based ART for HIV in pregnancy [53], we suspect that our findings would be similar in the dolutegravir era.

Conclusions

Children who were HEU and born to mothers living with HIV on ART had similar growth characteristics and immune profiles compared to children who were HUU. In this malaria hyper-endemic setting, children who were HEU had decreased risk for malaria and respiratory illness, which may be secondary to cotrimoxazole prophylaxis. These results highlight the importance of universal access to ART and high-quality healthcare for women living with HIV to optimize outcomes for both mothers and children.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12879-024-09051-3>.

Additional file 1: Supplementary Table 1. Sources of recombinant *P. falciparum* protein antigens, protein concentrations used in conjugation to magnetic microspheres, expression systems, and salient references. **Supplementary Table 2.** Birth characteristics of HEU and HUU infants. Mean gestational age, birth weight, length, and head circumference were compared between the two groups using the Student's t-test; sd, standard deviation. **Supplementary Table 3.** Linear growth curve models of Z scores for weight, length, head circumference, and BMI for age in HEU vs. HUU children, obtained using Bayesian hierarchical regression. HDI, highest probability density interval; sd, standard deviation. Region of practical equivalence (ROPE) for contrast terms for intercepts and slopes set at -0.05, 0.05. **Supplementary Table 4.** Fixed effects regression models for plasma cytokine levels. Twelve cytokines were measured at 8 visits (birth, 6, 10, 14, 18, 26, 39, and 52 weeks of age). A total of 663 visits were analyzed. Differences between HEU and HUU children in plasma cytokine trajectories were tested by evaluating the group*time interaction effect. If there was no difference, we tested whether HEU values differed from HUU values (group main effect) and whether values changed over time within a group (time main effect) (of interest was the 26 weeks vs. birth comparison, which is included in the table). **Supplementary Table 5.** Fixed effects regression models for vaccine-specific antibody levels. Antibodies against four vaccines were measured at 12 visits (birth, 6, 10, 14, 18 weeks, 6, 9, 12, 15, 18, 21, and 24 months of age). A total of 782 visits were analyzed. Differences between HEU and HUU children in vaccine antibody trajectories were tested by evaluating the group*time interaction effect. We then tested whether HEU values differed from HUU values (group main effect) and whether values changed over time within a group (time main effect) (of interest were the 6 months vs. birth and 18 months vs. 6 months comparisons, which are included in the table). **Supplementary Table 6.** Fixed effects regression models for antimalarial antibody levels (interaction effects and main effects for group). Antibodies against 14 *P. falciparum* antigens were measured at 12 visits (birth, 6, 10, 14, 18 weeks, 6, 9, 12, 15, 18, 21, and 24 months of age). A total of 1,135 visits were analyzed. Differences between HEU and HUU children in antimalarial antibody trajectories were tested by evaluating group*time interaction effect. For 12 of 14 antigens, we then tested whether HEU values differed from HUU values (group main effect); mean antibody values (fold over North

American controls) of the group averaged over all time points are listed.

Supplementary Table 7. Fixed effects regression models for antimalarial antibody levels (main effects for time). Antibodies against 14 *P. falciparum* antigens were measured at 12 visits (birth, 6, 10, 14, 18 weeks, 6, 9, 12, 15, 18, 21, and 24 months of age). A total of 1,135 visits were analyzed. For 12 of 14 antigens, we tested whether values changed over time independent of group. Of interest were 6 months vs. birth and 18 months vs. 6 months comparisons. Mean antibody values (fold over North American controls) at the three time points are listed.

Acknowledgements

We are grateful to all parents and guardians of participants for giving their consent and their cooperation. We thank all study and field team members at Chulaimbo Hospital and the Kisian Research Station. We thank Dr. Sheetij Dutta for providing Pf CSP protein, Dr. Evelina Angov for providing MSP1-42 (FVO), Dr. David Narum for providing AMA-1 and MSP3, and Dr. Alan Cowman for providing EBA-140, EBA-175, EBA-181, MSP DBL1, MSP DBL2, and RH5.

Authors' contributions

KRD analyzed all clinical data, helped to perform experiments, and drafted the manuscript. JER designed and performed all experiments, evaluated the data, and drafted the manuscript. SOO, IID, DM, and MMO developed and coordinated the cohort study and collected participant samples. SOO and IID provided funding for the project. MMO designed and performed some experiments. JGB provided antigens for the project, evaluated the data, and edited the manuscript. ASN and KRS analyzed the data and edited the manuscript. RR designed and coordinated the project and cohort study, evaluated the data, and provided funding. AED designed and coordinated the project and cohort study, evaluated the data, and provided funding. All authors reviewed and approved the manuscript.

Funding

This work was supported by the National Institutes of Health (grant numbers A1098511 [A.E.D.], CA102667 [R.R.], D43 153707 [S.O.O., I.I.D.], A1132644 [K.R.D.]).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The authors confirm that all experiments were performed in accordance with the Declaration of Helsinki. Informed consent to participate in this study was obtained from all the participants. Ethical approval was obtained from the University Hospitals Cleveland Medical Center IRB (08–07-09), Colorado Multiple IRB (15–1277), and Kenya Medical Research Institute (KEMRI) Scientific and Ethical Review Unit (NON SSC 089).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Center for Global Health & Diseases, Case Western Reserve University, 10900 Euclid Avenue LC: 4983, Cleveland, OH 44106, USA. ²Division of Pediatric Infectious Diseases, University Hospitals Rainbow Babies and Children's Hospital, LC: 4983, Cleveland, OH 44106, USA. ³Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. ⁴Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA. ⁵Burnet Institute, Melbourne, VIC, Australia. ⁶Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

Received: 16 June 2023 Accepted: 23 January 2024

Published online: 01 February 2024

References

- Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. *Lancet HIV*. 2016;3(1):e33–48.
- Song A, Liu X, Huang X, Meyers K, Oh DY, Hou J, et al. From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis. *Front Immunol*. 2018;9:212.
- Connor EM, Sperling RS, Gelber K, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med*. 1994;331(18):1173–80.
- Centers for Disease Control and Prevention (CDC). Birth outcomes following zidovudine therapy in pregnant women. *MMWR Morb Mortal Wkly Rep*. 1994;43(22):409;415–6.
- Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitoria M, Jan M, et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review. *AIDS*. 2014;28(Suppl 2):S105–18.
- Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS: Data 2020. Geneva. 2021. https://www.unaids.org/sites/default/files/media_asset/2020_aids_data-book_en.pdf. Accessed 29 Jan 2024.
- Astawesegn FH, Stulz V, Conroy E, Mannan H. Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-Saharan Africa. Evidence from panel data analysis. *BMC Infect Dis*. 2022;22(1):134.
- Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS DATA 2018. Geneva. 2018. https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf. Accessed 29 Jan 2024.
- Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. *Pediatr Infect Dis J*. 2007;26(6):519–26.
- Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of Infectious Morbidity in HIV-Exposed Uninfected Infants and Children. *Front Immunol*. 2016;7:164.
- Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2011;30(1):45–51.
- Pierre RB, Fulford TA, Lewis K, Palmer P, Walters C, Christie CDC. Infectious disease morbidity and growth among young HIV-exposed uninfected children in Jamaica. *Rev Panam Salud Publica*. 2016;40(6):401–9.
- Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Epidemiology of Acute Lower Respiratory Tract Infection in HIV-Exposed Uninfected Infants. *Pediatrics*. 2016;137(4):e20153272.
- Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et al. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. *J Trop Pediatr*. 2012;58(6):505–8.
- Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell RA. Mortality and health outcomes of HIV-exposed and unexposed children in a PMTCT cohort in Malawi. *PLoS ONE*. 2012;7(10):e47337.
- Ray JE, Dobbs KR, Ogolla SO, Daud II, Vulule J, Sumba PO, et al. Reduced Transplacental Transfer of Antimalarial Antibodies in Kenyan HIV-Exposed Uninfected Infants. *Open Forum Infect Dis*. 2019;6(6):ofz237.
- Zhou G, Afrane YA, Vardo-Zalik AM, Atieli H, Zhong D, Wamae P, et al. Changing patterns of malaria epidemiology between 2002 and 2010 in Western Kenya: the fall and rise of malaria. *PLoS ONE*. 2011;6(5):e20318.
- Hermesen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. *Mol Biochem Parasitol*. 2001;118(2):247–51.
- Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ, et al. Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. *PLoS Negl Trop Dis*. 2015;9(1):e0003466.
- Okoth F, Mbutia J, Gatheru Z, Murira F, Kanyingi F, Mugo F, et al. Sero-prevalence of hepatitis B markers in pregnant women in Kenya. *East Afr Med J*. 2006;83(9):485–93.
- Weber GE, White MT, Babakhanyan A, Sumba PO, Vulule J, Ely D, et al. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya. *Sci Rep*. 2017;7(1):16821.
- World Health Organization (WHO). Child growth standards. Available from: <https://www.who.int/tools/child-growth-standards>. Accessed 29 Jan 2024.
- Plummer M. JAGS: A Program for Analysis of Bayesian Graphical Models using Gibbs Sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003). Vienna. ISSN 1609-395X. <https://www.r-project.org/conferences/DSC-2003/Proceedings/Plummer.pdf>. Accessed 29 Jan 2024.
- Plummer MS, A.; Denwood, M. rjags: Bayesian Graphical Models using MCMC. 4–12 ed: CRAN. 2023. <https://mcmc-jags.sourceforge.io>. Accessed 29 Jan 2024.
- McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease C, Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2013;62(RR-04):1–34.
- Ramokolo V, Goga AE, Lombard C, Doherty T, Jackson DJ, Engebretsen IM. In Utero ART Exposure and Birth and Early Growth Outcomes Among HIV-Exposed Uninfected Infants Attending Immunization Services: Results From National PMTCT Surveillance, South Africa. *Open Forum Infect Dis*. 2017;4(4):ofx187.
- Jumare J, Datong P, Osawe S, Okolo F, Mohammed S, Inyang B, et al. Compromised Growth Among HIV-exposed Uninfected Compared With Unexposed Children in Nigeria. *Pediatr Infect Dis J*. 2019;38(3):280–6.
- Rosala-Hallas A, Bartlett JW, Filteau S. Growth of HIV-exposed uninfected, compared with HIV-unexposed, Zambian children: a longitudinal analysis from infancy to school age. *BMC Pediatr*. 2017;17(1):80.
- Omoni AO, Ntozini R, Evans C, Prendergast AJ, Moulton LH, Christian PS, et al. Child Growth According to Maternal and Child HIV Status in Zimbabwe. *Pediatr Infect Dis J*. 2017;36(9):869–76.
- Muskuwa MT, Estill J, Haas AD, van Oosterhout JJ, Tenthani L, Davies MA, et al. Weight gain of HIV-exposed, uninfected children born before and after introduction of the "Option B+" programme in Malawi. *AIDS*. 2018;32(15):2201–8.
- le Roux SM, Abrams EJ, Donald KA, Brittain K, Phillips TK, Zerbe A, et al. Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study. *The Lancet Child & adolescent health*. 2020;4(3):220–31.
- Lane CE, Bobrow EA, Ndatimana D, Ndaiyisaba GF, Adair LS. Determinants of growth in HIV-exposed and HIV-uninfected infants in the Kabehe Study. *Matern Child Nutr*. 2019;15(3):e12776.
- Brennan AT, Bonawitz R, Gill CJ, Thea DM, Kleinman M, Useem J, et al. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. *AIDS*. 2016;30(15):2351–60.
- Brennan AT, Bonawitz R, Gill CJ, Thea DM, Kleinman M, Long L, et al. A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-Exposed Uninfected Compared With HIV-Unexposed Uninfected Infants and Children. *J Acquir Immune Defic Syndr*. 2019;82(1):1–8.
- Yeganeh N, Watts DH, Xu J, Kerin T, Joao EC, Pilotto JH, et al. Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants: Results From the HPTN 040/PACTG 1043 Trial. *Pediatr Infect Dis J*. 2018;37(12):1271–8.
- Goetghebuer T, Smolen KK, Adler C, Das J, McBride T, Smits G, et al. Initiation of Antiretroviral Therapy Before Pregnancy Reduces the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-exposed Uninfected Infants Born in a High-income Country. *Clin Infect Dis*. 2019;68(7):1193–203.
- Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. *Lancet*. 2006;367(9518):1256–61.
- Mbye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, Wandeler G, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. *Trop Med Int Health*. 2014;19(9):1057–67.
- Sandison TG, Homby J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. *BMJ*. 2011;342:d1617.

40. Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, et al. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. *Lancet HIV*. 2015;2(4):e137–50.
41. Guidelines on Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults. Geneva, Switzerland: World Health Organization; 2006.
42. Lockman S, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S, et al. Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial. *Lancet Glob Health*. 2017;5(5):e491–500.
43. Daniels B, Coutoudis A, Moodley-Govender E, Mulol H, Spooner E, Kiepiela P, et al. Effect of co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in South Africa: a randomised controlled, non-inferiority trial. *Lancet Glob Health*. 2019;7(12):e1717–27.
44. Daniels B, Kuhn L, Spooner E, Mulol H, Goga A, Feucht U, et al. Cotrimoxazole guidelines for infants who are HIV-exposed but uninfected: a call for a public health and ethics approach to the evidence. *Lancet Glob Health*. 2022;10(8):e1198–203.
45. Oliveira LM, Lima JF, Cervantes CA, Casseb JS, Mendonca M, Duarte AJ, et al. Increased frequency of circulating Tc22/Th22 cells and polyfunctional CD38(-) T cells in HIV-exposed uninfected subjects. *Sci Rep*. 2015;5:13883.
46. Moncunill G, Dobano C, Gonzalez R, Smolen KK, Manaca MN, Balcells R, et al. Association of Maternal Factors and HIV Infection With Innate Cytokine Responses of Delivering Mothers and Newborns in Mozambique. *Front Microbiol*. 2020;11:1452.
47. Amenyogbe N, Dimitriu P, Cho P, Ruck C, Fortuno ES 3rd, Cai B, et al. Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner. *J Immunol*. 2020;205(10):2618–28.
48. Uffman EA, Li SH, Chen JL, Allen N, Boiditswe S, Fouda GG, et al. Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana. *Vaccine*. 2022;40(33):4764–71.
49. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesselting AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. *JAMA*. 2011;305(6):576–84.
50. Reikie BA, Naidoo S, Ruck CE, Slogrove AL, de Beer C, la Grange H, et al. Antibody responses to vaccination among South African HIV-exposed and unexposed uninfected infants during the first 2 years of life. *Clin Vaccine Immunol*. 2013;20(1):33–8.
51. Simani OE, Izu A, Violaro A, Cotton MF, van Niekerk N, Adrian PV, et al. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. *AIDS*. 2014;28(4):531–41.
52. Crawley J, Sismanidis C, Goodman T, Milligan P. malaria WHOACosrt-vuitEPoliirIPTf. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. *Lancet*. 2012;380(9846):1001–10.
53. Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, et al. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. *N Engl J Med*. 2022;387(9):799–809.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.